Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director

Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in biomarker and augmented intelligence solutions for chronic low back pain, has granted an inducement stock option to Daniel Keefe, its newly appointed Commercial Director for the Western U.S. The option, agreed upon as a material inducement for Keefe's employment, covers 17,000 shares of common stock at an exercise price of $3.20 per share, the closing price on the grant date of May 5, 2026.

The grant was approved by the compensation committee of Aclarion's board of directors in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years, with one-fourth vesting on the one-year anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the subsequent three years, contingent on Keefe's continued service. The option carries a 10-year term and is governed by an inducement stock option agreement.

This expansion of Aclarion's commercial team signals increasing demand for the company's flagship product, Nociscan, a SaaS platform that noninvasively helps physicians identify painful discs in the lumbar spine using magnetic resonance spectroscopy (MRS) data. The platform, which has seen triple-digit growth in utilization, processes MRS data through proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain. These biomarker data are then analyzed by proprietary augmented intelligence algorithms to indicate whether a disc may be a source of pain, providing critical insights for treatment planning.

The addition of a dedicated commercial director for the Western U.S. is a strategic move to capitalize on the growing adoption of Nociscan. As the company continues to expand its reach, it aims to address the chronic low back pain market, which affects millions of patients and represents a significant healthcare burden. By helping physicians distinguish between painful and nonpainful discs, Nociscan has the potential to improve treatment success rates and reduce unnecessary procedures.

Aclarion's forward-looking statements in the press release caution that actual results may differ due to various risks and uncertainties, including market acceptance and competitive factors. The company encourages readers to review its filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025. For more information, visit www.aclarion.com.